68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2016

Conditions

Recurrent Prostate Carcinoma

Interventions

PROCEDURE

Computed Tomography

Part of PET/CT scan

DRUG

Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)

Intravenously-administered (IV) radioisotope

PROCEDURE

Magnetic Resonance Imaging

Part of PET/MRI scan

PROCEDURE

Positron Emission Tomography

Part of PET/CT and/or PET/MRI scans

Trial Locations (1)

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Stanford University

OTHER

NCT02488070 - 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter